{"analyses":[{"ciLowerLimit":"0.10","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.28","groupIds":["OG000","OG001"],"nonInferiorityComment":"IRC, RECIST v1.1 Stratified Analysis (by race (Asian vs non-Asian) and CNS metastases at baseline by IRC)","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Cause-Specific Hazard Ratio","paramValue":"0.16","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8"},{"groupId":"OG001","value":"45.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"description":"CNS progression was assessed as percentage of participants with an event defined as time from randomization until first radiographic evidence of CNS progression by IRC. The risk for a CNS progression without a prior non-CNS progression with alectinib compared with crizotinib.","groups":[{"description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Alectinib"},{"description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG001","title":"Crizotinib"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Randomization to CNS PD as first occurrence of disease progression (assessed every 8 weeks up to 33 months)","title":"Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using RECIST V1.1 Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}